1
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
SOVALDI safely and effectively. See full prescribing information
for SOVALDI.
SOVALDI
®
(sofosbuvir) tablets, for oral use
SOVALDI
®
(sofosbuvir) oral pellets
Initial U.S. Approval: 2013
WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN
PATIENTS COINFECTED WITH HCV AND HBV
See full prescribing information for complete boxed warning.
Hepatitis B virus (HBV) reactivation has been reported, in some
cases resulting in fulminant hepatitis, hepatic failure, and death.
(5.1)
-----------------------------RECENT MAJOR CHANGES-------------------------
Indications and Usage (1) 08/2019
Dosage and Administration
Recommended Dosage in Pediatric Patients 3 Years of
Age and Older with Genotype 2 or 3 HCV (2.3) 08/2019
Preparation and Administration of Oral Pellets (2.4) 08/2019
------------------------------INDICATIONS AND USAGE--------------------------
SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B
polymerase inhibitor indicated for the treatment of:
• Adult patients with genotype 1, 2, 3 or 4 chronic HCV infection
without cirrhosis or with compensated cirrhosis as a component of a
combination antiviral treatment regimen. (1)
• Pediatric patients 3 years of age and older with genotype 2 or 3
chronic HCV infection without cirrhosis or with compensated
cirrhosis in combination with ribavirin. (1)
------------------------DOSAGE AND ADMINISTRATION----------------------
• Testing Prior to the Initiation of Therapy: Test all patients for HBV
infection by measuring HBsAg and anti-HBc. (2.1)
• Recommended dosage in adults: One 400 mg tablet taken once
daily with or without food. (2.2)
• Recommended dosage in pediatric patients 3 years of age and
older: Recommended dosage of SOVALDI in pediatric patients 3
years of age and older with genotype 2 or 3 HCV using SOVALDI
tablets or oral pellets is based on weight. Refer to Table 3 of the full
prescribing information for specific dosing guidelines based on body
weight. (2.3)
• HCV/HIV-1 coinfection: For adult and pediatric patients with
HCV/HIV-1 coinfection, follow the dosage recommendations in the
tables below, respectively. (2.2, 2.3)
• Recommended adult treatment regimen and duration: (2.2)
Treatment-naïve without cirrhosis
or with compensated cirrhosis
(Child-Pugh A)
SOVALDI +
peginterferon
alfa + ribavirin
12 weeks
Treatment-naïve and treatment-
experienced without cirrhosis or
with compensated cirrhosis
(Child-Pugh A)
SOVALDI +
ribavirin
12 weeks
Treatment-naïve and treatment-
experienced without cirrhosis or
with compensated cirrhosis
(Child-Pugh A)
SOVALDI +
ribavirin
24 weeks
• SOVALDI in combination with ribavirin for 24 weeks can be
considered for adult patients with genotype 1 infection who are
interferon ineligible. (2.2)
• Should be used in combination with ribavirin for treatment of HCV in
adult patients with hepatocellular carcinoma awaiting liver
transplantation for up to 48 weeks or until liver transplantation,
whichever occurs first. (2.2)
• Recommended treatment regimen and duration for pediatric patients
3 years of age and older: (2.3, 2.4)
Pediatric Patient Population
3 Years of Age and Older
Treatment-naïve and treatment-
experienced without cirrhosis or
with compensated cirrhosis
(Child-Pugh A)
SOVALDI +
ribavirin
12 weeks
Treatment-naïve and treatment-
experienced without cirrhosis or
with compensated cirrhosis
(Child-Pugh A)
SOVALDI +
ribavirin
24 weeks
• A dosage recommendation cannot be made for patients with severe
renal impairment or end stage renal disease. (2.7, 8.6)
• Instructions for Use should be followed for preparation and
administration of SOVALDI oral pellets. (2.4)
-----------------------DOSAGE FORMS AND STRENGTHS--------------------
• Tablets: 400 mg and 200 mg of sofosbuvir. (3)
• Oral Pellets: 200 mg and 150 mg of sofosbuvir. (3)
--------------------------------CONTRAINDICATIONS------------------------------
• When used in combination with peginterferon alfa/ribavirin or ribavirin
alone, all contraindications to peginterferon alfa and/or ribavirin also
apply to SOVALDI combination therapy. (4)
-------------------------WARNINGS AND PRECAUTIONS----------------------
• Risk of Hepatitis B Virus Reactivation: Test all patients for evidence of
current or prior HBV infection before initiation of HCV treatment.
Monitor HCV/HBV coinfected patients for HBV reactivation and
hepatitis flare during HCV treatment and post-treatment follow-up.
Initiate appropriate patient management for HBV infection as clinically
indicated. (5.1)
• Bradycardia with amiodarone coadministration: Serious symptomatic
bradycardia may occur in patients taking amiodarone with a
sofosbuvir-containing regimen, particularly in patients also receiving
beta blockers, or those with underlying cardiac comorbidities and/or
advanced liver disease. Coadministration of amiodarone with
SOVALDI is not recommended. In patients without alternative, viable
treatment options, cardiac monitoring is recommended. (5.2, 6.2, 7.1)
--------------------------------ADVERSE REACTIONS-----------------------------
• The most common adverse events (incidence greater than or equal to
20%, all grades) observed with SOVALDI in combination with ribavirin
were fatigue and headache. The most common adverse events
observed with SOVALDI in combination with peginterferon alfa and
ribavirin were fatigue, headache, nausea, insomnia and anemia.
(6.1). The most common adverse events observed with SOVALDI in
combination with ribavirin oral solution in pediatric patients was
decreased appetite. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Gilead
Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
---------------------------------DRUG INTERACTIONS-----------------------------
• Coadministration of amiodarone with a sofosbuvir-containing regimen
may result in serious symptomatic bradycardia. (5.2, 6.2, 7.1)
• Drugs that are intestinal P-gp inducers (e.g., rifampin, St. John’s wort)
may alter the concentrations of sofosbuvir. (5.3, 7, 12.3)
• Consult the full prescribing information prior to use for potential drug-
drug interactions. (5.2, 5.3, 7, 12.3)
• Clearance of HCV infection with direct acting antivirals may lead to
changes in hepatic function, which may impact safe and effective use
of concomitant medications. Frequent monitoring of relevant
laboratory parameters (INR or blood glucose) and dose adjustments
of certain concomitant medications may be necessary. (7.1)
---------------------------USE IN SPECIFIC POPULATIONS--------------------
• Patients with HCV/HIV-1 coinfection: Safety and efficacy have been
studied. (14.4)
• Patients with hepatocellular carcinoma awaiting liver transplantation:
Safety and efficacy have been studied. (8.8)
See 17 for PATIENT COUNSELING INFORMATION and
FDA-approved patient labeling.
Revised: 03/2020